These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 35679523)

  • 1. Systematic reviews of randomized controlled trials of cannabinoid products in chronic pain conditions and for symptoms associated with multiple sclerosis: what do they tell us?
    Vila Silván C; Vaney C; Dykukha I
    Expert Rev Clin Pharmacol; 2022 Apr; 15(4):415-431. PubMed ID: 35679523
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Use of Cannabis and Cannabinoids in Treating Symptoms of Multiple Sclerosis: a Systematic Review of Reviews.
    Nielsen S; Germanos R; Weier M; Pollard J; Degenhardt L; Hall W; Buckley N; Farrell M
    Curr Neurol Neurosci Rep; 2018 Feb; 18(2):8. PubMed ID: 29442178
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy, tolerability and safety of cannabis-based medicines for chronic pain management - An overview of systematic reviews.
    Häuser W; Petzke F; Fitzcharles MA
    Eur J Pain; 2018 Mar; 22(3):455-470. PubMed ID: 29034533
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A systematic review of pharmacological pain management in multiple sclerosis.
    Jawahar R; Oh U; Yang S; Lapane KL
    Drugs; 2013 Oct; 73(15):1711-22. PubMed ID: 24085618
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cannabinoids for treatment of chronic non-cancer pain; a systematic review of randomized trials.
    Lynch ME; Campbell F
    Br J Clin Pharmacol; 2011 Nov; 72(5):735-44. PubMed ID: 21426373
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cannabinoids for Treatment of MS Symptoms: State of the Evidence.
    Rice J; Cameron M
    Curr Neurol Neurosci Rep; 2018 Jun; 18(8):50. PubMed ID: 29923025
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Systematic review of safeness and therapeutic efficacy of cannabis in patients with multiple sclerosis, neuropathic pain, and in oncological patients treated with chemotherapy].
    Amato L; Minozzi S; Mitrova Z; Parmelli E; Saulle R; Cruciani F; Vecchi S; Davoli M
    Epidemiol Prev; 2017; 41(5-6):279-293. PubMed ID: 29119763
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Efficacy, tolerability and safety of cannabinoids for chronic neuropathic pain: A systematic review of randomized controlled studies].
    Petzke F; Enax-Krumova EK; Häuser W
    Schmerz; 2016 Feb; 30(1):62-88. PubMed ID: 26830780
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Meta-analysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain.
    Iskedjian M; Bereza B; Gordon A; Piwko C; Einarson TR
    Curr Med Res Opin; 2007 Jan; 23(1):17-24. PubMed ID: 17257464
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Herbal medicinal products or preparations for neuropathic pain.
    Boyd A; Bleakley C; Hurley DA; Gill C; Hannon-Fletcher M; Bell P; McDonough S
    Cochrane Database Syst Rev; 2019 Apr; 4(4):CD010528. PubMed ID: 30938843
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of Efficacy and Tolerability of Medicinal Cannabinoids in Patients With Multiple Sclerosis: A Systematic Review and Meta-analysis.
    Torres-Moreno MC; Papaseit E; Torrens M; Farré M
    JAMA Netw Open; 2018 Oct; 1(6):e183485. PubMed ID: 30646241
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effectiveness of cannabinoids in the management of chronic nonmalignant neuropathic pain: a systematic review.
    Boychuk DG; Goddard G; Mauro G; Orellana MF
    J Oral Facial Pain Headache; 2015; 29(1):7-14. PubMed ID: 25635955
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adherence to Consolidated Standards of Reporting Trials (CONSORT) Guidelines for Reporting Safety Outcomes in Trials of Cannabinoids for Chronic Pain: Protocol for a Systematic Review.
    Mohiuddin MM; Mizubuti G; Haroutounian S; Smith S; Campbell F; Park R; Gilron I
    JMIR Res Protoc; 2019 Jan; 8(1):e11637. PubMed ID: 30688655
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [There is evidence for the use of cannabinoids for symptomatic treatment of multiple sclerosis].
    Bazinski H; Jensen HB; Stenager E
    Ugeskr Laeger; 2015 May; 177(20):956-60. PubMed ID: 26535431
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cannabinoids for the Treatment of Chronic Non-Cancer Pain: An Updated Systematic Review of Randomized Controlled Trials.
    Lynch ME; Ware MA
    J Neuroimmune Pharmacol; 2015 Jun; 10(2):293-301. PubMed ID: 25796592
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of cannabinoids in the treatment of pain and (painful) spasticity.
    Karst M; Wippermann S; Ahrens J
    Drugs; 2010 Dec; 70(18):2409-38. PubMed ID: 21142261
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [There is evidence for the use of cannabinoids for symptomatic treatment of multiple sclerosis].
    Basinski H; Jensen HB; Stenager E
    Ugeskr Laeger; 2014 Mar; 176(12A):. PubMed ID: 25350886
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic evaluation of nabiximols for the treatment of multiple sclerosis pain.
    Tanasescu R; Constantinescu CS
    Expert Opin Drug Metab Toxicol; 2013 Sep; 9(9):1219-28. PubMed ID: 23621668
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Medical Marijuana for Treatment of Chronic Pain and Other Medical and Psychiatric Problems: A Clinical Review.
    Hill KP
    JAMA; 2015 Jun 23-30; 313(24):2474-83. PubMed ID: 26103031
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.